Sarcoidosis
Sarcoidosis is a multisystem granulomatous inflammatory disease of unknown etiology characterized by non-caseating granulomas, most commonly in the lungs (>90%) but with capacity to involve essentially any organ — skin, eyes, heart, nervous system, liver, kidneys, joints. Presentations range from asymptomatic incidental hilar lymphadenopathy through the classic acute Löfgren's syndrome (erythema nodosum + bilateral hilar lymphadenopathy + arthralgia/fever, generally self-resolving with good prognosis) to chronic progressive multisystem disease with organ-threatening complications. Diagnosis: tissue biopsy showing non-caseating granulomas + exclusion of TB, fungal infection, beryllium exposure, hypersensitivity pneumonitis. Standard-of-care: observation in asymptomatic disease; glucocorticoids (prednisone 20-40 mg/day pulmonary, higher for neurosarcoidosis or cardiac); methotrexate first-line steroid-sparing; azathioprine + mycophenolate + leflunomide additional steroid-sparing options; hydroxychloroquine for cutaneous and hypercalcemia; TNF inhibitors (infliximab + adalimumab) for refractory or severe organ-threatening disease; emerging NRP2-targeting candidate efzofitimod (aTyr Pharma, EFZO-FIT Phase 3 readout 2025) — first novel sarcoidosis-specific Phase 3 in decades. VITAMIN D AVOIDANCE LOAD-BEARING — sarcoid macrophages constitutively activate vitamin D outside renal regulation; supplementation can precipitate hypercalcemia. Cardiac sarcoidosis carries sudden cardiac death risk. ATS/ERS/WASOG joint statement + AAN neurosarcoidosis + Foundation for Sarcoidosis Research. Thirty-second deliberate non-elevation.
What changes during this transition
Sarcoidosis is the 32nd life-stage axis where Juno has chosen deliberate non-elevation: substrate exists on individual peptide pages so that /ask answers honestly when users probe, but no peptide is surfaced as a discovery card from this hub. The reasoning is load-bearing for the disease. Sarcoidosis is not a single-organ inflammatory condition that a generalized 'anti-inflammatory' or 'regenerative' peptide could plausibly modulate. It is a CD4+ Th1/Th17-driven granulomatous immune dysregulation in which macrophages and T-cells organize into non-caseating granulomas of unknown etiologic trigger, with the capacity to affect essentially every organ system. The standard-of-care toolkit — glucocorticoids, methotrexate, mycophenolate, leflunomide, hydroxychloroquine for cutaneous and hypercalcemia contexts, TNF inhibitors (infliximab and adalimumab) for refractory or organ-threatening disease, repository corticotropin in selected cases, and the emerging Phase 3 NRP2-receptor candidate efzofitimod (aTyr Pharma, EFZO-FIT readout) — works by suppressing or redirecting that specific T-cell and macrophage program. Every peptide we considered for this substrate runs in the wrong direction relative to that program. BPC-157 is sold as a generalized inflammation-and-healing peptide, but its published mechanism (VEGF/NO axis, gut-brain signaling, tendon/wound healing) does not engage the CD4+ Th1/Th17 granuloma machinery and has zero clinical data in any granulomatous disease at any phase, including from the Zagreb group that originated it. TB-500 reaches the conversation through the pulmonary-fibrosis fear thread — roughly 20% of sarcoid patients progress to fibrotic Scadding stage IV disease — but anti-fibrotic adjunct without immunosuppression is the wrong altitude when the upstream driver is unaddressed granulomatous inflammation; pirfenidone and nintedanib have actual evidence in progressive fibrosing ILD where TB-500 has none. Thymosin alpha-1 is the cleanest Rule 6 case: registered for chronic hepatitis B in multiple jurisdictions (China, Italy, others) and explored as a T-cell-activating adjuvant in sepsis and oncology, but T-cell activation in a Th1/Th17-driven granulomatous disease is mechanistically the wrong direction, and HBV registration does not propagate to granulomatous immune-mediated disease. LL-37 extends the autoimmune-contraindication thread that runs through the cathelicidin substrate family — cathelicidins are upregulated in sarcoid granulomas, drive innate immune amplification, and feed the type I interferon signature that the disease shares with psoriasis and lupus; this is directionally pro-disease, not therapeutic. NMN is the general-aging NAD+ precursor without any sarcoid trial anchor; the unique disease-specific concern is not NMN itself but the vitamin D and calcium polypharmacy that travels with consumer NAD+ stacks — sarcoid macrophages activate vitamin D outside normal renal regulation, hypercalcemia affects 10-30% of patients, and vitamin D supplementation can precipitate clinical hypercalcemia. The editorial position is that surfacing any of these as a discovery option on a sarcoidosis hub would imply an adjunct relationship to a disease where no adjunct relationship has been established in any jurisdiction, where the mechanistic arguments for the candidates we considered all run the wrong direction, and where the standard-of-care toolkit is specific and effective. Substrate is the honest place to answer 'what about [peptide]?' when users arrive at /ask having already encountered the peptide in community spaces. Elevation to discovery is the dishonest move when no peptide belongs in the protocol.
Important caveat
Sarcoidosis is a multisystem disease with two safety threads that we want users to carry into every conversation about peptides, supplements, or lifestyle interventions, because each is specific to this disease in a way that general health framing buries. VITAMIN D ACTIVATION AND HYPERCALCEMIA IS THE LOAD-BEARING SUPPLEMENT SAFETY THREAD. Sarcoid macrophages constitutively express 1-alpha-hydroxylase and convert 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D outside the renal feedback regulation that normally limits this conversion. The downstream effect is calcium dysregulation: hypercalcemia occurs in roughly 10-30% of sarcoid patients, hypercalciuria in roughly 50%, and the consequences include nephrolithiasis, nephrocalcinosis, granulomatous interstitial nephritis, and acute kidney injury. Vitamin D supplementation can precipitate or worsen clinical hypercalcemia in active sarcoidosis, and consumer health culture is saturated with vitamin D supplementation — multivitamins, calcium-vitamin D combinations for bone health, 'longevity stacks,' NAD+ protocols that bundle vitamin D, immune-support blends, and direct-to-consumer micronutrient panels that flag any sub-optimal D level as a deficiency to correct. Sarcoid patients are routinely over-supplemented inadvertently. Before adding any supplement, peptide stack, or longevity protocol, screen every ingredient label for vitamin D (cholecalciferol, ergocalciferol, calcifediol, calcitriol, vitamin D2/D3) and calcium, and have the disclosure with the sarcoid-experienced specialist explicitly. The specialist may want serum calcium, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, 24-hour urinary calcium, and renal imaging baseline before any change. CARDIAC SARCOIDOSIS IS THE EMERGENCY FRAMING. Cardiac involvement appears in up to 25% of sarcoid patients on autopsy series and is often subclinical until a sentinel event — conduction abnormalities (AV block of varying degree), ventricular arrhythmias (sustained VT, sudden cardiac death), and heart failure (restrictive or dilated cardiomyopathy from granulomatous infiltration and fibrosis) are the canonical presentations. Sudden cardiac death is the lethal outcome the cardiology and pulmonology communities track. Diagnostic workup: CMR with late gadolinium enhancement + FDG-PET for active inflammation, with EP study and device consideration (ICD, pacemaker) in selected cases. Any sarcoid patient with new palpitations, syncope, presyncope, exertional dyspnea, or unexplained arrhythmia on ECG needs urgent cardiac evaluation — this is not a stable outpatient referral but a same-week or same-day evaluation depending on symptom severity. Peptides with any cardiovascular signaling are not a sensible addition to a sarcoid patient with unevaluated cardiac risk, and the load-bearing action is to confirm cardiac status with the specialist before considering any peptide. Standard-of-care escalation in sarcoidosis depends on disease severity and organ involvement. Asymptomatic disease — particularly Löfgren's syndrome — frequently self-resolves and is managed with observation; many cases require no pharmacotherapy. Symptomatic pulmonary disease, ocular involvement (anterior or posterior uveitis, which can be sight-threatening), neurosarcoidosis (cranial neuropathies — facial nerve most common — meningeal involvement, parenchymal lesions, hypothalamic-pituitary involvement, spinal cord involvement), and cardiac sarcoidosis are managed with glucocorticoids (prednisone, with dose tailored to organ involvement and severity), methotrexate as the first-line steroid-sparing agent (with a 6-12 month onset of action), azathioprine, mycophenolate, leflunomide, and hydroxychloroquine particularly for cutaneous involvement and hypercalcemia. TNF inhibitors (infliximab, adalimumab) are reserved for refractory disease and are particularly used in neurosarcoidosis, severe ocular involvement, lupus pernio, and other organ-threatening contexts. Repository corticotropin injection has historical FDA approval. The emerging Phase 3 candidate efzofitimod (aTyr Pharma, NRP2 receptor agonist, EFZO-FIT trial readout) is the first novel sarcoidosis-specific Phase 3 program in decades. JAK inhibitors (tofacitinib in particular) have generated case-report interest for cutaneous sarcoid. None of this is replaced or improved upon by any peptide currently in the consumer market. The ATS/ERS/WASOG joint statement on sarcoidosis treatment, AAN guidance for neurosarcoidosis, and AASLD guidance for hepatic involvement are the dominant clinical guidance documents internationally. Patient advocacy through the Foundation for Sarcoidosis Research (FSR), the American Lung Association sarcoidosis resources, Sarcoidosis UK, and equivalent organizations is the appropriate non-clinical support layer. WADA athletes: BPC-157 (S0) and TB-500 (S2) prohibited at all times — neither has a sarcoidosis use case anyway, and glucocorticoids carry separate WADA TUE considerations.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.